The effects of antiviral therapy on the distribution of herpes simplex virus type 1 to ganglionic neurons and its consequences during, immediately following and several months after treatment.
Both famciclovir (FCV) and valaciclovir (VACV) are potent inhibitors of herpes simplex virus type 1 (HSV-1) in a murine cutaneous infection model. The object of the present study was to determine whether either drug had an effect on the anatomical distribution of infected neurons in the peripheral nervous system and to assess the consequences for infected cells during, immediately following and several months after a 9 day period of continuous treatment. Mice were inoculated via the neck with a recombinant strain of HSV-1 expressing the lacZ reporter gene under the immediate-early gene promoter. Sensory ganglia were sampled daily up to day 11 post-inoculation (p.i.) and infected cells were detected by means of the reporter gene product. Ganglia were also removed at 1.5 and 10 months p.i. and latency was assessed by explant co-cultivation and by using in situ hybridization to detect LAT-expressing neurons. While both drugs reduced the severity of acute infection markedly, neither compound completely prevented the relentless distribution of infection among peripheral nervous tissue. Furthermore, there was a difference between the compounds regarding the expression of the reporter gene during and after termination of treatment and in the number of residual LAT-positive neurons.
Thackray
Alana M
AM
Centre for Veterinary Science, Cambridge University, Madingley Road, Cambridge CB3 0ES, UK1.
Field
Hugh J
HJ
Centre for Veterinary Science, Cambridge University, Madingley Road, Cambridge CB3 0ES, UK1.
D015075:2-Aminopurine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000212:Acyclovir / Q000031:analogs & derivatives / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use*; D000077595:Famciclovir; D005724:Ganglia / Q000821:virology*; D017930:Genes, Reporter; D006561:Herpes Simplex / Q000188:drug therapy* / Q000821:virology; D018259:Herpesvirus 1, Human / Q000302:isolation & purification*; D017403:In Situ Hybridization; D007763:Lac Operon; D051379:Mice; D009474:Neurons / Q000821:virology*; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D017735:Virus Latency; D001616:beta-Galactosidase / Q000378:metabolism
D000998:Antiviral Agents; D015075:2-Aminopurine; D001616:beta-Galactosidase; D014633:Valine; D000077483:Valacyclovir; D000077595:Famciclovir; D000212:Acyclovir